Ангедония как базовый синдром и мишень для терапевтического воздействия при депрессивном расстройстве
https://doi.org/10.31363/2313-7053-2019-3-10-18
Аннотация
В статье представлен аналитический обзор, нацеленный на определение влияния ангедонии на течение и терапевтический прогноз при депрессии. В настоящее время не существует определенного и специфического фармакологического подхода к лечению ангедонии при депрессии, хотя ясно, что все антидепрессанты, влияющие на симптомы депрессии в целом, действуют в определенной степени на ангедонию. Описаны современные взгляды на биологические механизмы, вовлеченные в формирование ангедонии, на основании которых возможен поиск препаратов с антиангедонической активностью. Представлены данные, на основании которых вортиоксетин может быть рассмотрен как анти- депрессант со специфическим антиангедоническим эффектом.
Об авторах
Г. Э. Мазо
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Россия
Россия
Мазо Галина Элевна — д.м.н., ученый секретарь, руководитель отделения эндокринологической психиатрии
А. О. Кибитов
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России
Россия
Россия
Кибитов Александр Олегович — д.м.н., руководитель лаборатории молекулярной генетики; ведущий научный сотрудник отделения эндокринологической психиатрии
Список литературы
1. Депрессия и риск развития соматических заболеваний. Руководство для врачей (под редакцией Незнанов Н.Г., Мазо Г.Э., Кибитов А.О.) — М. Спец. Изд-во мед. кн., 2018; 248. [Depressiya i risk razvitiya somaticheskikh zabolevani. I. Rukovodstvo dlya vrachei (pod redaktsiei Neznanov N.G., Mazo G.E., Kibitov A.O.) — M. Spets. Izdatel’stvo med.kn., 2018; 248.] (In Russ.)
2. Мазо Г.Э., Незнанов Н.Г. Депрессивное расстройство/– М. ГЭОТАР–Медиа, Москва. — 2018. — 112с. (Серия «Библиотека врача-специалиста») [Mazo G.E., Neznanov N.G. Depressivnoe rasstroistvо. — M. GEHOTAR–MediA, Moskvа. — 2018. — 112s. (Seriya «Biblioteka vracha-spetsialista»)] (In Russ.)
3. Незнанов Н.Г., Мазо Г.Э., Рукавишников Г.В. Влияние антидепрессантов на когнитивные функции пациентов с депрессивным расстройством. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2015; 3:75–82. [Neznanov N.G., Mazo G.E., Rukavishnikov G.V. Vliyanie antidepressantov na kognitivnye funktsii patsientov s depressivnym rasstroistvoм. // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. BekhterevA. 2015; 3:75-82] (InRuss.)
4. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence. 2012; 6:369–388. DOI: 10.2147/PPA.S29716
5. Ameli R, Luckenbaugh DA., Gould NF., Kathleen Holmes M, Lally N, Ballard ED, & ZarateCA. SHAPS-C: The Snaith-Hamilton pleasure scale modified for clinician administration. PeerJ. 2014; 1:e429. https://doi.org/10.7717/peerj.429
6. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-(2-(2,4-dimethylphenylsulfanylphenylpiperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. — J Med Chem. 2011; 54:3206-3221. DOI: 10.1021/jm101459g
7. Betry C, Etievant A, Pehrsonb A, Sanchez C, Haddjeri N. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory — Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2015; 58:38–46. doi.org/10.1016/j.pnpbp.2014.12.002
8. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuro-psychopharmacology. 1997; 16:333-338. DOI.org/10.1016/S0893-133X(96)00242-4
9. Boyer P, Tassin JP, Falissart B, Troy S. Sequential improvement of anxiety, depression and anhedonia with sertra- line treatment in patients with major depression. J. Clin. Pharm. Ther. 2000; 25:363–371. PMID: 11123488
10. Brivio P, Corsini G, Riva MA, Calabrese F. Chronic vortioxetine treatment improves the responsive ness to an acute stress acting through the ventral hippocampus in a glucocorticoid-dependent way. Pharmacol Res. 2019; 142:14-21. doi: 10.1016/j.phrs.2019.02.006.
11. Buckner JD, Joiner TE Jr, Pettit JW, Lewinsohn PM, Schmidt NB. Implications of the DSM’s emphasis on sadness and anhedonia in major depressive disorder. Psychiatry Res. 2008; 159:25–30. DOI: 10.1016/j.psychres.2007.05.010
12. Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan Set al.,. Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroa- daptations in a mouse model of depression. PLoS One. 2017; 12: e0188043
13. Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L and McIntyre RS. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Front. Psychiatry. 2019; 10:17. doi: 10.3389/fpsyt.2019.00017
14. Cao B, Zhu J, Zuckerman H, Rosenblat J, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre R. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019; 92:109-117. DOI.org/10.1016/j.pnpbp.2019.01.002.
15. Carter J, Swardfager W. Mood and metabolism: Anhedonia as a clinical target in Type 2 diabetes. Psychoneuroendocrinology. 2016; 69:123-132. doi: 10.1016/j.psyneuen.2016.04.002
16. Caviedes A, Lafourcade C, Soto C, Wyneken U. BDNF/NF-κB Signaling in the Neurobiology of Depression. Curr Pharm Des. 2017; 23:3154-3163. DOI: 10.2174/1381612823666170111141915
17. Cléry-Melin ML1, Jollant F1, Gorwood P1. Reward systems and cognitions in Major Depressive DisorderCNS Spectr. 2019; 24:64-77. DOI: 10.1017/S1092852918001335
18. Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behav Brain Res. 2019; 372:112041. doi: 10.1016/j.bbr.2019.112041.
19. Cooper JA, Arulpragasam AR, Treadway MT. Anhedonia in depression: biological mechanisms and computational models. CurrOpinBehav Sci. 2018; 22:128-135. doi: 10.1016/j.cobeha.2018.01.024.
20. Corruble E, de Bodinat C, Belaidi C, Goodwin GM Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int. J. Neuropsychopharmacol. 2013; 16: 2219–2234. doi. org/10.1017/S1461145713000679
21. Davidson, K.W., Burg, M.M., Kronish, I.M., Shimbo, D., Dettenborn, L., Mehran, R., et al.,. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch. Gen. Psychiatry. 2010; 67:480–488. DOI: 10.1001/archgenpsychiatry.2010.36
22. Detre TP, Jarecki H. Modern Psychiatric Treatment. Lippincott, Philadelphia, PA: Lippincott. 1971.
23. Dryman A, Eaton WW. Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr. Scand. 1991; 84:1–5.
24. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010; 68(8):748-7 54. doi:10.1016/j.biopsych.2010.06.010.
25. Farabaugh A, Fisher L, NyerM, Holt D, Cohen M, Baer L, et al. Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: implications for mechanisms of change. Ann. Clin. Psychiatry. 2015; 27:118–126. PMID: 25954938
26. Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: An emerging therapeutic target. Progress in Neuro-Psychopharmacology & Biological Psychiatr. 2002; 26:1019–1027. PMID: 12452521
27. Fawcett J. The morbidity and mortality of clinical depression. Special Issue: affective disorders: current and future perspectives. Int. Clin. Psychopharmacol. 1993; 8:217–220.
28. Fox ME, Lobo MK. The molecular and cellular mechanisms of depression: a focus on reward circuitry. Mol Psychiatry. 2019; 9. DOI: 10.1038/s41380-019-0415-3.
29. Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007; 99:83–89. DOI: 10.1016/j.jad.2006.08.020;
30. Franken IHA, Zijlstra C, Muris P. Are nonpharmacological induced rewards related to anhedonia? A study among skydivers. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006; 30:297–300. DOI.org/10.1016/j.pnpbp.2005.10.011
31. Ghanei Gheshlagh R, Parizad N, Sayehmiri K, The relationship between depression and metabolic syndrome: systematic review and meta-analysis study. Iran Red Crescent Med. J. 2016; 18:e26523. DOI: 10.5812/ircmj.26523
32. Gold MS, Blum K, Febo M, Baron D, Modestino EJ, Elman I., Badgaiyan RD. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and antireward systems. Front Biosci (Schol Ed). 2018; 10:309-325. DOI:10.2741/s518
33. Gorwood P. Neurobiological mechanisms of anhedonia // Dialogues in Clinical Neuroscience. 2008; 3: 291–299.
34. Hamer JA, Testani D, Mansur RB, Lee Y, Subramaniapillai M, McIntyre RS. Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. Exp Neurol. 2019; 315:1-8. DOI: 10.1016/j.expneurol.2019.01.016. Epub 2019Jan 26.
35. Harsing LG Jr, Prauda I, Barkoczy J, et al. A 5-HT7 heteroreceptor-mediated inhibition of (3H) serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interac tion. — Neurochem Res 2004;29(8):1487-97. DOI. org/10.1023/B:NERE.0000029560.14262.39
36. Hasler BP, John Allen JB, David Sbarra A, Richard Bootzin R, Rebecca Bernert A. Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalignment in nonseasonal depression. Psychiatry Res. 2010;178:205–207. doi: 10.1016/j.psychres.2010.04.027
37. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and substance dependence: clinical correlates and treatment options. Front. Psych. 2011; 2:10. doi: 10.3389/fpsyt.2011.00010
38. Heininga VE, Dejonckheere E, Houben M, Obbels J, Sienaert P, Leroy B, van Roy J, Kuppens P. The dynamical signature of anhedonia in major depressive disorder: positive emotion dynamics, reactivity, and recovery. BMC Psychiatry. 2019; 19:59. doi: 10.1186/s12888-018-1983-5
39. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Dis. 1998; 50:97-108.
40. Kaviani H, Gray J, Checkley S, Raven P, Wilson G, Kumari V. Affective modulation of the startle response in depression: influence of the severity of depression, anhedonia, and anxiety. Journal of Affective Disorders. 2004; 83:21–31. DOI.org/10.1016/j.jad.2004.04.007
41. Kennedy S.H. Core symptoms of major depressive disorder: relevance to diagnosis and treatment // Dialogues in Clinical Neuroscience. 2008; 10:271–277. PMID: 18979940
42. Keranen AM, Rasinaho E, Hakko H, Savolainen M, Lindeman S. Eating behavior in obese and overweight persons with and without anhedonia. Appetite. 2010; 55:726–729. doi.org/10.1016/j.appet. 2010.08.012
43. Klein D. Endogenomorphic depression. A conceptual and terminological revision. Arch. Gen. Psychiatry. 1974; 31:447–454.
44. Klein D. Depression and anhedonia. In: Clark, C., Fawcett, J. (Eds.), Anhedonia and Affect Deficit States. PMA Publishing, New York. 1984; Р. 1–14. 45. Kłodzińska A, Tatarczyńska E, Stachowicz K, Chojnacka-Wójcik E. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J PhysiolPharmacol. 2004; 55:113-126.
45. Komulainen T, Keranen AM, Rasinaho E, Hakko H, Savolainen MJ, Kujari ML et al. Quitting a weight loss program is associated with anhedonia: preliminary findings of the lifestyle intervention treatment evaluation study in northern Finland. Int. J. Circumpolar Health. 2011; 70:72–78. DOI: 10.3402/ijch.v70i1.17795
46. Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience. 2010; 166(4):1023-1035. DOI:10.1016/j.neuroscience.2010.01.036.
47. Kugathasan P, Waller J, Westrich L, Abdourahman A, Tamm JA, Pehrson AL, Dale E, Gulinello M, Sanchez C, Li Y. In vivo and in vitro effects of vortioxetine on molecules associated with neuroplasticity. J Psychopharmacol. 2017; 31:365-376. doi: 10.1177/0269881116667710.
48. Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate Jr. CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J. Psychopharmacol. 2015; 29:596–607. doi: 10.1177/0269881114568041
49. Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS NeurosciTher. 2018; 24:615-623. doi: 10.1111/cns.12854.
50. Laursen B, Bundgaard CH, Graversen C, Grupe M, Sanchez C, Leiser SC, Sorensen HBD, Drewes AM, Bastlund JF. Acute dosing of vortioxetine strengthens event-related brain activity associated with engagement of attention and cognitive functioning in rats. Brain Res. 2017; 1664:37-47. DOI: 10.1016/j.brainres.2017.03.024.
51. Loas G, Dalleau E, Lecointe H, Yon V. Relationships between anhedonia, alexithymia, impulsivity, suicidal ideation, recent suicide attempt, C-reactive protein and serum lipid levels among 122 inpatients with mood or anxious disorders. Psychiatry Res. 2016; 246:296-302. doi: 10.1016/j.psychres.2016.09.056.
52. Loas G, Pierson A, Anhedonia in psychiatry: a review. Ann. Med. Psychol. Paris. 1989; 147:705–717.
53. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stressinduced depressive rats. Brain Res Bull. 2018; 142:1-7. DOI: 10.1016/j.brainresbull.2018.06.007
54. Malhi, G.S., Berk, M., 2007. Does dopamine dysfunction drive depression? Acta Psychiatr. Scand. 115 (Suppl 433), 116–1247 doi.org/10.1111/j.1600-0447.2007.00969.x
55. Martinotti G., Carli V., Tedeschi D., Di Giannantonio M, Roy A, Janiri L, Sarchiapone M. Monoand polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses. Addict. Behav. 2009;34 (9):790–793
56. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola, M, Onofrj M, Janiri L, Di Giannantonio M. Agomelatine versus Venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J. Clin. Psychopharmacol. 2012;32 (4): 487–491. doi.org/10.1016/S0924-9338(12)74135-4
57. Mathews JR, Barch DM. Episodic memory for emotional and non-emotional words in individuals with anhedonia. Psychiatry Research 2006;143: 121–133. doi.org/10.1016/j.psychres.2005.07.030
58. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a metaanalysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016; 19(10) . DOI: 10.1093/ijnp/ pyw055:
59. McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF, Brent DA. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J. Am. Acad. ChildAdolesc. Psychiatry2012; 51:404–411. DOI: 10.1016/j.jaac.2012.01.011
60. Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. PharmacolBiochemBehav. 2013 Apr; 105: 41-50. /DOI. org/10.1016/j.pbb.2013.01.019
61. Nefs G, Pop VJ, Denollet J, Pouwer F. Depressive symptoms and all-causemortality in people with type 2 diabetes: a focus on potential mechanisms. Br. J.Psychiatry. 2016; 209 (2):142–149. DOI: 10.1192/bjp.bp.114.154781
62. NIMH. Definitions of the RDoC Domains and Constructs (2018). Available online at: https://www.nimh.nih.gov/research- priorities/rdoc/definitions-of- the- rdoc- domains- and- constructs.shtml
63. Oei TI, Verhoeven WM, Westenberg HG, Zwart FM, van Ree JM, Anhedonia, suicide ideation and dexamethasone nonsuppression in depressed patients. J. Psychiatr. Res. 1990; 24: 25–35
64. Olie JP, Kasper S, Efficacy of agomelatine, a MT1/ MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. J. Neuropsychopharmacol. 2007;10 (5):661–673. DOI: 10.1017/S1461145707007766
65. Pan Z, Rosenblat JD, Swardfager W3, McIntyre RS4. Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. Curr Pharm Des. 2017;23(14):2065-2072. doi: 10.2174/1381612823666170111144340;
66. Pan, A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. DiabetesCare. 2012;35(5):1171–1180. doi: 10.2337/dc11-2055
67. Parker G, Hadzi-Pavlovic D. 1996. Melancholia: A Disorder of Movement and Mood. Cambridge University Press, Cambridge, UK
68. Paykel ES, Scott J, Teasdale JD, Johnson AL Garland A, Moore R, et al Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56:829–835
69. Pedrotti MF, Karen J, Taiane C, Thaíse M, Vieira SI, Magalhães P, Kapczinski F, Souza L, Silva R, Oses J, Wiener C, Metabolic syndrome, depression and anhedonia among young adults. Psychiatry Research. 2019;271:306–310. doi.org/10.1016/j.psychres.2018.08.009
70. Pehrson AL, Pedersen CS, Tølbøl KS, Sanchez C. Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Front Pharmacol. 2018; 6(9):162. DOI: 10.3389/fphar.2018.00162.
71. Pérez PD, Ma Z, Hamilton C, Sánchez C, Mørk A, Pehrson AL, Bundgaard C, Zhang N. Acute effects of vortioxetine and duloxetine on resting-state functional connectivity in the awake rat. Neuropharmacology. 2018; 128:379-387. doi: 10.1016/j.neuropharm.2017.10.038.
72. Perry PJ, Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J. Affect. Disord. 1996; 39:1–6. PMID: 8835647
73. Pintor L, Torres X, Navarro V, Matrai S, Gasto C. Is the type of remission after a major depressive episode and important risk factor to relapse in a 4-year follow-up? J Affect Disord. 2004; 82:291-296. doi.org/10.1016/j.jad.2003.11.008
74. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014; 10:393-423. doi: 10.1146/annurev-clinpsy-050212-185606.;
75. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011; 12:574–587. doi.org/10.3109/15622975.2011.595823
76. Ribot T, 1896. La Psychologie Des Sentiments. Felix Alcan, Paris. 78. Riga MS1, Sánchez C2, Celada P1, Artigas F3. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology. 2016; 108:73-81. doi: 10.1016/j.neuropharm. 2016.04.023.
77. Rizvi SJ, Lambert C, Kennedy S. Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions. Curr Psychiatry Rep. 2018; 20(2):13. doi: 10.1007/s11920-018-0877-z;
78. Romer Thomsen K, Whybrow PC, Kringelbach ML. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Front Behav. Neurosci. 2015; 9:497. DOI: 10.3389/fnbeh.2015.00049
79. Sagud M, Nikolac Perkovic M, Vuksan-Cusa B, Maravic A, SvobStrac D, Mihaljevic Peles A, Zivkovic M, Kusevic Z, Pivac N. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology (Berl). 2016; 233(17):3259-3267. doi: 10.1007/s00213-016-4364-0.
80. Schrader GD. Does anhedonia correlate with depression severity in chronic depression? Compr. Psychiatry. 1997; 38:260–263.
81. Shankman SA, Katz AC, DeLizza AA, Sarapas C, Gorka SM, Campbell ML. The different facets of anhedonia and their associations with different psychopathologies. In: Anhedonia: A Comprehensive Handbook Volume. 2014; 3–22.
82. Silverstone PH. Is anhedonia a good measure of depression? Acta Psychiatr. Scand. 1991; 83:249–250. 85. Spijker J, Bijl RV, de Graaf R, Nolen WA. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr. Scand. 2001; 103:122–130. DOI.org/10.1034/j.1600-0447.2001.103002122.x
83. Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr. 2008; 13(7):561-565. DOI: 10.1017/S1092852900016837
84. Vortioxetine exerts antiinflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018; 175:113-124. DOI: 10.1111/bph.14074.
85. Taylor DJ, Walters HM, Vittengl JR, et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J. Affect. Disord. 2010; 123:181–187. doi: 10.1016/j.jad.2009.08.007
86. Treadway MT. The neurobiology of motivational deficits in depression — an update on candidate pathomechanisms // Current Topics in Behavioral Neurosciences. 2016; 27:337-355. DOI: 10.1007/7854_2015_400
87. Treadway MT, ZaldDH.. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci. Biobehav. Rev. 2011; 35(3):537–5557. doi: 10.1016/j.neubiorev.2010.06.006
88. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JG, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol. Med. 2008; 38:289–300. DOI: 10.1017/S0033291707001730
89. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P. Depression symptom dimensions as predictors of anti- depressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol. Med. 2012; 42:967–980. DOI: 10.1017/S0033291711001905
90. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P. de Boer P. et al., Reduced reward learning predicts outcome in major depressive disorder. Biol. Psychiatry. 2013; 73:639–645. DOI: 10.1016/j.biopsych.2012.10.014
91. Waller JA, Nygaard SH, Li Y, duJardin KG, Tamm JA, Abdourahman A, Elfving B, Pehrson AL, Sánchez C, Wernersson R. Neuroplasticity pathway sand protein-interaction networks are modulated by vortioxetine inrodents. BMC Neurosci. 2017; 18:56. DOI: 10.1186/s12868-017-0376-x.
92. Waller JA, Tamm JA, Abdourahman A, Pehrson AL, Li Y, Cajina M, Sánchez C. Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. Eur Neuropsychopharmacol. 2017; 27(2):192-203. DOI: 10.1016/j.euroneuro.2016.11.014.
93. Winer ES, Drapeau CW, Veilleux JC, Nadorff MR. The Association between anhedonia, suicidal ideation, and suicide attempts in a large student sample. Arch. Suicide Res.: Off. J. Int. Acad. Suicide Res. 2016; 20: 265–2727. DOI: 10.1080/13811118.2015.1025119
94. Yan G, Zhang M, Liu Y, Yin M. Efficacy of vortioxetine combined cognitive behaviour intervention therapy on brain-derived neurotrophic factor level on depressive patients. Psychogeriatrics. 2019. doi: 10.1111/psyg.12426.
95. Yin L, Xu X, Chen G, Mehta ND, Haroon E, Miller AH, Luo Y, Li Z, Felger JC. Inflammation and decreased functional connectivity in a widely-distributed network in depression: Centralized effects in the ventral medial prefrontal cortex. Brain Behav Immun. 2019; 80:657-666. DOI: 10.1016/j.bbi.2019.05.011.
Рецензия
Для цитирования:
Мазо Г.Э., Кибитов А.О. Ангедония как базовый синдром и мишень для терапевтического воздействия при депрессивном расстройстве. Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. 2019;(3):10-18. https://doi.org/10.31363/2313-7053-2019-3-10-18
For citation:
Mazo G.E., Kibitov A.O. Anhedonia as a basic syndrome and a target for treatment for depressive disorder. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(3):10-18. (In Russ.) https://doi.org/10.31363/2313-7053-2019-3-10-18
Просмотров: 3807
Послать статью по эл. почте 